Focused On-demand Library for VIP36-like protein

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q9H0V9

UPID:

LMA2L_HUMAN

Alternative names:

Lectin mannose-binding 2-like

Alternative UPACC:

Q9H0V9; B4DSH3; D3DXH6; Q53GV3; Q53S67; Q63HN6; Q8NBQ6; Q9BQ14

Background:

The VIP36-like protein, also known as Lectin mannose-binding 2-like, plays a crucial role in cellular processes. It is primarily involved in the regulation of export from the endoplasmic reticulum of a subset of glycoproteins and functions as a regulator of ERGIC-53. This protein's unique regulatory mechanisms underscore its importance in maintaining cellular homeostasis and protein trafficking.

Therapeutic significance:

VIP36-like protein's association with Intellectual developmental disorder, autosomal recessive 52, and Intellectual developmental disorder, autosomal dominant 69, highlights its potential as a therapeutic target. Understanding the role of VIP36-like protein could open doors to potential therapeutic strategies, offering hope for interventions in these intellectual developmental disorders.